Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries - results of an online survey.

Malmros K, Huttner BD, McNulty C, Rodríguez-Baño J, Pulcini C, Tängdén T; ESGAP UTI working group.

Int J Antimicrob Agents. 2019 Jun 20. pii: S0924-8579(19)30168-2. doi: 10.1016/j.ijantimicag.2019.06.015. [Epub ahead of print]

PMID:
31229671
2.

Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men.

Montelin H, Forsman KJ, Tängdén T.

PLoS One. 2019 Jan 25;14(1):e0211098. doi: 10.1371/journal.pone.0211098. eCollection 2019.

3.

Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.

Skarp KP, Shams A, Montelin H, Lagerbäck P, Tängdén T.

Int J Antimicrob Agents. 2019 Jan;53(1):74-79. doi: 10.1016/j.ijantimicag.2018.09.011. Epub 2018 Sep 17.

PMID:
30236958
4.

Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.

Tängdén T, Cojutti PG, Roberts JA, Pea F.

Clin Pharmacokinet. 2018 Nov;57(11):1399-1405. doi: 10.1007/s40262-018-0638-5.

PMID:
29546589
5.

Unavailability of old antibiotics threatens effective treatment for common bacterial infections.

Tängdén T, Pulcini C, Aagaard H, Balasegaram M, Hara GL, Nathwani D, Sharland M, Theuretzbacher U, Cars O.

Lancet Infect Dis. 2018 Mar;18(3):242-244. doi: 10.1016/S1473-3099(18)30075-6. No abstract available. Erratum in: Lancet Infect Dis. 2018 Feb 28;:.

PMID:
29485082
6.

Automated time-lapse microscopy a novel method for screening of antibiotic combination effects against multidrug-resistant Gram-negative bacteria.

Ungphakorn W, Lagerbäck P, Nielsen EI, Tängdén T.

Clin Microbiol Infect. 2018 Jul;24(7):778.e7-778.e14. doi: 10.1016/j.cmi.2017.10.029. Epub 2017 Nov 3.

7.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
8.

Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.

Tängdén T, Karvanen M, Friberg LE, Odenholt I, Cars O.

Infect Dis (Lond). 2017 Jul;49(7):521-527. doi: 10.1080/23744235.2017.1296183. Epub 2017 Mar 6.

PMID:
28264618
9.

A Novel Microfluidic Assay for Rapid Phenotypic Antibiotic Susceptibility Testing of Bacteria Detected in Clinical Blood Cultures.

Malmberg C, Yuen P, Spaak J, Cars O, Tängdén T, Lagerbäck P.

PLoS One. 2016 Dec 14;11(12):e0167356. doi: 10.1371/journal.pone.0167356. eCollection 2016.

10.

Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics.

Ungphakorn W, Malmberg C, Lagerbäck P, Cars O, Nielsen EI, Tängdén T.

J Microbiol Methods. 2017 Jan;132:69-75. doi: 10.1016/j.mimet.2016.11.001. Epub 2016 Nov 9.

PMID:
27836633
11.

Target Product Profile for a Diagnostic Assay to Differentiate between Bacterial and Non-Bacterial Infections and Reduce Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus.

Dittrich S, Tadesse BT, Moussy F, Chua A, Zorzet A, Tängdén T, Dolinger DL, Page AL, Crump JA, D'Acremont V, Bassat Q, Lubell Y, Newton PN, Heinrich N, Rodwell TJ, González IJ.

PLoS One. 2016 Aug 25;11(8):e0161721. doi: 10.1371/journal.pone.0161721. eCollection 2016.

12.

Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments.

Lagerbäck P, Khine WW, Giske CG, Tängdén T.

J Antimicrob Chemother. 2016 Aug;71(8):2321-5. doi: 10.1093/jac/dkw213. Epub 2016 Jun 21.

PMID:
27334665
13.

A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.

Ungphakorn W, Tängdén T, Sandegren L, Nielsen EI.

J Antimicrob Chemother. 2016 Sep;71(9):2521-33. doi: 10.1093/jac/dkw205. Epub 2016 Jun 20.

PMID:
27330073
14.

A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases.

Jonsson AK, Larsson A, Tängdén T, Melhus Å, Lannergård A.

Infect Ecol Epidemiol. 2015 Nov 9;5:28224. doi: 10.3402/iee.v5.28224. eCollection 2015.

15.

[Cross allergy between penicillins and other beta lactam antibiotics--the risk is much less than previously thought].

Tängden T, Furebring M, Löwdin E, Werner S.

Lakartidningen. 2015 Feb 3;112. pii: C9A4. Review. Swedish.

16.
17.

Silver resistance genes are overrepresented among Escherichia coli isolates with CTX-M production.

Sütterlin S, Edquist P, Sandegren L, Adler M, Tängdén T, Drobni M, Olsen B, Melhus A.

Appl Environ Microbiol. 2014 Nov;80(22):6863-9. doi: 10.1128/AEM.01803-14. Epub 2014 Aug 15.

18.

Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.

Tängdén T.

Ups J Med Sci. 2014 May;119(2):149-53. doi: 10.3109/03009734.2014.899279. Epub 2014 Mar 26. Review.

19.

Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O.

Antimicrob Agents Chemother. 2014;58(3):1757-62. doi: 10.1128/AAC.00741-13. Epub 2014 Jan 6.

20.

[Carbapenem-resistant Escherichia coli now exist in Sweden].

Ljungquist O, Kjölvmark C, Tängdén T.

Lakartidningen. 2013 Aug 7-20;110(32-33):1401-2. Swedish. No abstract available.

PMID:
23980379
21.

Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.

Tängdén T, Adler M, Cars O, Sandegren L, Löwdin E.

J Antimicrob Chemother. 2013 Jun;68(6):1319-26. doi: 10.1093/jac/dkt044. Epub 2013 Mar 10.

PMID:
23478794
22.

Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases.

Tängdén T, Enblad P, Ullberg M, Sjölin J.

Clin Infect Dis. 2011 Jun;52(11):1310-6. doi: 10.1093/cid/cir197. Epub 2011 May 2.

PMID:
21540208
23.

Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.

Tängdén T, Eriksson BM, Melhus A, Svennblad B, Cars O.

J Antimicrob Chemother. 2011 May;66(5):1161-7. doi: 10.1093/jac/dkr053. Epub 2011 Mar 4.

PMID:
21393158
24.

Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.

Tängdén T, Cars O, Melhus A, Löwdin E.

Antimicrob Agents Chemother. 2010 Sep;54(9):3564-8. doi: 10.1128/AAC.00220-10. Epub 2010 Jun 14.

Supplemental Content

Loading ...
Support Center